Status:
UNKNOWN
Fatty Acid Metabolism in Carriers of Apolipoprotein E Epsilon 4 Allele: Determining the Blood-to-brain Link
Lead Sponsor:
Université de Sherbrooke
Conditions:
Healthy
Eligibility:
All Genders
30-50 years
Phase:
NA
Brief Summary
In Canada, \~17 millions of adults between 30-64 y old could benefit from a prevention strategy to lower the risk of Alzheimer's disease (AD). Although a lot of epidemiological studies reported positi...
Eligibility Criteria
Inclusion
- \- Men and women aged between 30-50 years old.
Exclusion
- Tobacco use,
- Malnutrition (assessed from blood albumin, hemoglobin and lipids),
- Diabetes,
- Participants taking an EPA+DHA supplement or consuming more than 2 fish meals per week,
- Uncontrolled thyroid, renal and endocrine disorder disease,
- Chronic immune condition or inflammation (CRP \> 10 mg/l, white cell count),
- Cancer,
- Recent major surgery or cardiac event,
- Pregnant or lactating women,
- Pre-menopause or menopause,
- Dementia,
- Ongoing or past severe drug or alcohol abuse,
- Psychiatric difficulties or major depression
- Ongoing or past intensive physical training.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04279743
Start Date
August 1 2020
End Date
April 1 2025
Last Update
May 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Recherche sur le Vieillissement
Sherbrooke, Quebec, Canada, J1H 4C4